Bright Path Labs Receives FDA AMT Designation for Medicines
Mesa, Arizona, U.S., September 14, 2026 Bright Path Labs, a U.S.-based pharmaceutical manufacturer, announced that the U.S. Food and...
Phase 2 clinical trial
Advertisement
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Kenvue’s TYLENOL With Naproxen Shows Lasting Pain Relief
Fort Washington, Pennsylvania, U.S., September 8, 2026 New clinical evidence presented at PAINWeek 2026 highlights the potential of a...
INBRX-106 Doubles Response Rate in Phase 2 HNSCC
San Diego, California, U.S., September 8, 2026 Inhibrx Biosciences, Inc. has reported positive primary endpoint results from the randomized...
Advertisements
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
Inhibrx to Present INBRX-106 Phase 2 HNSCC Results
San Diego, California, USA, September 4, 2026 Inhibrx Biosciences, Inc. has announced plans to host a live webcast presentation...
PMV Pharma Reports 46% ORR in Ovarian Cancer Trial
PRINCETON, N.J., August 31, 2026 PMV Pharmaceuticals announced updated interim data from the Phase 2 pivotal portion of the...
Tolerance Bio Licenses Long-Acting IL-7 Therapy
Philadelphia, Pennsylvania, August 19, 2026 Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function,...
Advertisement
